• Hetao Huang, Minghui Luo, Haodong Liang, Jianke Pan, Weiyi Yang, Lingfeng Zeng, Guihong Liang, Senrong Hou, Jinlong Zhao, and Jun Liu.
• Second School of Clinical Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China.
• Pain Med. 2021 Feb 23; 22 (2): 352-362.

ObjectiveTo compare the efficacy and safety of celecoxib and diclofenac sodium in patients with knee osteoarthritis (KOA).MethodsClinical controlled trials (CCTs) and randomized controlled trials (RCTs) from online databases comparing the efficacy of celecoxib and diclofenac sodium in the treatment of KOA were retrieved. The main outcomes included the treatment effect, C-reactive protein (CRP) level, erythrocyte sedimentation rate (ESR), visual analog scale (VAS) score, and complication rate. The Cochrane risk of bias (ROB) tool in Review Manager 5.3.5 was used to assess methodological quality.ResultsTwelve studies (N = 2,350) were included in this meta-analysis. The meta-analysis indicated that celecoxib reduced pain more effectively than diclofenac sodium in patients with KOA, as evaluated by the VAS score. In addition, celecoxib has certain advantages in terms of better treatment effects and greater reductions in the ESR, CRP level, and complication rate.ConclusionsCelecoxib is superior to diclofenac sodium in the treatment of KOA. However, well-designed and high-quality RCTs are still needed.© The Author(s) 2020. Published by Oxford University Press on behalf of the American Academy of Pain Medicine.

13 keywords...

hide…